Pyrrolopyrimidine nucleosides and analogs thereof
View Patent ↗The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein R c and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.
1. A compound of Formula II:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof, wherein:
Y is —C(O)—, or
wherein X 1 is independently O, NH, or S, X 2 is independently a bond, —O—, —S—, or —NH—, and X 3 is independently —OR, —NHR II , or —SR II ;
each R is independently —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo, R 1 , —OR 1 , —NR 1 R 2 , —SR 1 , —OC(O)R 1 , —C(O)OR 1 , —NHC(O)OR 1 , or —NHC(O)R 1 ;
R a and R b are each independently, at each occurrence, —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo —OR 1 , —NR 1 R 2 , —SR 1 , —OC(O)R 1 , —C(O)OR 1 —NHC(O)OR 1 , or —NHC(O)R 1 ;
R 1 and R 2 are each independently, at each occurrence, —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo, —R 3 , —R 4 , —OR 3 , —NR 3 R 4 , —SR 3 , —OC(O)R 3 , —C(O)OR 3 , —NHC(O)OR 3 , or —NHC(O)R 3 ;
R 3 and R 4 are each independently, at each occurrence, —H, —C 1 -C 20 alkyl, —C 2 -C 20 alkenyl, —C 2 -C 20 alkynyl, —C 3 -C 8 cycloalkyl, —C 4 -C 8 cycloalkenyl, aryl, heteroaryl, or heterocyclyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more halogen, oxo, aryl, heteroaryl, —OH, —NH 2 , —SH, —OC(O)H, —C(O)OH, —NHC(O)OH, or —NHC(O)H;
R c is independently —H or -D; and
n is independently 0, 1, 2 or 3.
2. The compound of claim 1 , wherein R a is —H.
3. The compound of claim 1 , wherein R b is —H.
4. The compound of claim 1 , wherein R c is —H.
5. The compound of claim 1 , wherein n is 0.
6. The compound of claim 1 , wherein R a , R b and R c are —H.
7. The compound of claim 1 , wherein R a , R b and R c are —H and n is 0.
8. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
9. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
10. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
11. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
12. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
13. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
14. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
15. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
16. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
17. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
18. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
19. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
20. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
21. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
22. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
23. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
24. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
25. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
26. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof, and a pharmaceutically acceptable carrier.
27. The pharmaceutical composition of claim 26 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof, and a pharmaceutically acceptable carrier.
28. A method of treating a viral infection or a viral-infection associated disease or disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
29. A method of treating a viral infection or a viral-infection associated disease or disorder comprising administering to a subject in need thereof an effective amount of the compound:
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate or mixture thereof.
30. The method of claim 29 wherein the viral infection is norovirus.